Sign up to save your podcasts
Or
Share BIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in type 2 diabetes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in type 2 diabetes
CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients.
View all episodes
By BiotechTV
4.3
66 ratings
CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients.
More shows like BiotechTV - News
View all
We Study Billionaires - The Investor’s Podcast Network
3,376 Listeners
Bloomberg Businessweek
421 Listeners
WSJ Tech News Briefing
1,650 Listeners
The Meb Faber Show - Better Investing
947 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
321 Listeners
Value Investing with Legends
211 Listeners
Fiction - Comedy Fiction
6,443 Listeners
Biotech 2050 Podcast
62 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,020 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
21 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
3 Listeners
BioVenture VoiCes with Chris Garabedian
5 Listeners
Cheeky Pint
37 Listeners